The European malaria vaccine development association

Objective

The goal of the European Malaria Vaccine Development Association (EMVDA) integrated project is to systematically develop and test prototype malaria vaccines by comparative and continuous evaluation of candidate vaccines and move these as quickly as possible to clinical studies. Our emphasis will be on 'downstream' vaccine pre- clinical development and clinical trials. A product development management structure will be set up that will be responsible for the technical and regulatory management of the transition of candidate vaccines between the production groups and clinical testing groups. Exploiting the capabilities of 3 SMEs, 9 European malaria vaccine research centres, the European Malaria Vaccine Initiative (EMVI) and the African Malaria Network (AMANET), we aim to establish a scientific and technological structure supported by effective management. Stringent go/no-go criteria will be used to assess and compare competing antigens and delivery systems to focus resources on to the most credible vaccine candidates. Our internal Training Programme, which will be integrated with that of the existing Framework Programme 6 funded malaria-oriented Network of Excellence (BIOMALPAR) will promote interdisciplinary collaboration and support for our African partners, AMANET, particularly with their training programmes for young African scientists. Working closely with our African partners, standard operating procedures governing all in vitro and in vivo immuno-assays used by the consortium during vaccine development will be developed and distributed. The EMVDA project brings together Europe's leading malaria vaccine researchers and pan-Union initiatives in an unprecedented collaboration with vaccine SMEs and the African Malaria Network to drive the production and clinical development of an effective vaccine to protect those vulnerable to this disease and thus aid human development.'

Field of science

• /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines
• /social sciences/other social sciences/social sciences interdisciplinary/sustainable development
• /medical and health sciences/health sciences/infectious disease/malaria

Programme(s)

• FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006.

Topic(s)

• LSH-2005-2.3.0-3 - Rational design of malaria vaccine

Call for proposal

FP6-2005-LIFESCIHEALTH-6
See other projects for this call

Funding Scheme

IP - Integrated Project

Coordinator

EUROPEAN VACCINE INITIATIVE

Address

Im Neuenheimer Feld 307
Heidelberg
Germany

Participants (15)

CRUCELL HOLLAND B.V.

Netherlands

Address

Archimedesweg 4
Leiden

PEVION BIOTECH LTD.

Switzerland

Address

Rehhagstrasse 79
Berne

CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

Address

University Offices, Weillington Square
Oxford

FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTRE

Netherlands

Address

Lange Kleiweg 139
3306 Rijswijk

THE UNIVERSITY OF EDINBURGH

United Kingdom

Address

Old College, South Bridge
Edinburgh

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

Address

Geert Grooteplein-noord 9
9101 Nijmegen

MEDICAL RESEARCH COUNCIL

United Kingdom

Address

20 Park Crescent
London

AFRICAN MALARIA NETWORK TRUST

Tanzania

Address

Ali Hassan Mwinyi Road
33207 Dar Es Salaam

SWISS TROPICAL INSTITUTE

Switzerland

Address

Socinstr.57
Basel

STOCKHOLM UNIVERSITY

Sweden

Address

Universitetsvägen 10
Stockholm

HOSPICES CANTONAUX CHUV

Switzerland

Address

Rue Du Bugnon 21
Lausanne

EBERHARD-KARLS UNIVERSITAET TUEBINGEN

Germany

Address

Wilhelmstrasse 7
Tübingen

ETNA BIOTECH S.R.L.

Italy

Address

Piazza Stesicoro 59
Catania

RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG

Germany

Address

Seminarstrasse 2
Heidelberg

STATENS SERUM INSTITUT

Denmark

Address

Artillerivej 5
Copenhagen S